Skip to main content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know:

Get the latest public health information from CDC:

Get the latest research information from NIH:


Placeholder slot

This page contains brief information about rituximab and a collection of links to more information about the use of this drug, research results, and ongoing clinical trials.

US Brand Name(s)
FDA Approved

FDA label information for this drug is available at DailyMed.

Use in Cancer

Rituximab is approved to be used in adults either alone or with other drugs to treat:

Rituximab is also being studied in the treatment of other conditions and types of cancer.

Rituximab is also available in a different form, combined with hyaluronidase. For more information, see the Drug Information Summary for Rituximab and Hyaluronidase Human.

More About Rituximab

Definition from the NCI Drug Dictionary - Detailed scientific definition and other names for this drug.

MedlinePlus Information on Rituximab - A lay language summary of important information about this drug that may include the following:

  • warnings about this drug,
  • what this drug is used for and how it is used,
  • what you should tell your doctor before using this drug,
  • what you should know about this drug before using it,
  • other drugs that may interact with this drug, and
  • possible side effects.

Drugs are often studied to find out if they can help treat or prevent conditions other than the ones they are approved for. This patient information sheet applies only to approved uses of the drug. However, much of the information may also apply to unapproved uses that are being studied.

Research Results and Related Resources

Monoclonal Antibodies

Approval Expanded for Venetoclax in Chronic Lymphocytic Leukemia

Drug Combination Improves Outlook for Some Patients with Chronic Lymphocytic Leukemia

Rituximab Retreatment After Disease Progression Is Comparable to Rituximab Maintenance Therapy in Patients With Low-Tumor Burden Follicular Lymphoma

Combination of Idelalisib and Rituximab Improves Survival in Patients With Relapsed Chronic Lymphocytic Leukemia

Study Suggests New Treatment Option for Some Lymphomas

Targeted Cancer Therapies

Clinical Trials Accepting Patients

Find Clinical Trials for Rituximab - Check for trials from NCI's list of cancer clinical trials now accepting patients.

  • Posted:
  • Updated: